ZetrOZ is taking aim at the multibillion-dollar chronic pain management market with sam, its newly launched, first-of-its kind, wearable long-duration ultrasound therapy device.

A preview of the emerging health ncompanies profiled in the current issue of Start-Up. This month's profile group, "Noninvasive Body Contouring Begins To Take Shape," features profiles of EndyMed, Slender Medical and Zeltiq. Plus these Start-Ups Across Health Care: Auxogyn, Mucosis, NuVue Therapeutics, Taiga Biotechnologies and ZetrOZ.

Traditional home treatments for chronic pain, such as topical creams, hot pads, cold packs, prescription drugs and transcutaneous nerve stimulation are plentiful, yet only half of America's chronic pain sufferers report their pain as under control. Consumers may soon have a better option for treating their pain: a wearable ultrasound system that is portable, affordable and easy to use. TheraSonX from ZetrOZ LLC uses low-intensity ultrasound delivered through an iPod-sized applicator to provide continuous therapy for up to six hours while patients are engaged in normal activities.

ZymoGenetics shareholders who want a better offer than the $885 million acquisition Bristol-Myers Squibb offered on Wednesday, September 8, aren’t likely to get one. It’s a disappointing result for a company with nearly 30 years of biotech discovery and grand ambitions behind it.